Morningstar

Novo Nordisk AS Class B NOVO B Stock

Stock Price as of DKK

Company Profile NOVO B

Business Description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1, Bagsvaerd 2880
T +45 44448888
phak@novonordisk.com opens in a new tab
www.novonordisk.com opens in a new tab
Sector
Healthcare
Industry
Drug Manufacturers - General
Most Recent Earnings
Mar 31, 2025
Fiscal Year End
Dec 31, 2025
Employees
77,406
As of Mar 31, 2025

Sustainability

ESG Risk Rating Assessment
Highest Controversy Level (1 = Low, 5 = Severe)
Significant
Incidents: Customer
ESG Risk Rating
22.97
Medium
Negligible
0–9.99
Low
10–19.99
Medium
20–29.99
High
30–39.99
Severe
40+
Highest Controversy Level (1 = Low, 5 = Severe)
Incidents: Customer
Top Material ESG Issues
Product Governance
Overall
Access to Basic Services
Overall
Human Capital
Overall
ESG Risk Rating is as of Jun 04, 2025. Highest Controversy Level is as of Jul 08, 2025. Sustainalytics Subindustry: Pharmaceuticals. Sustainalytics provides Morningstar with company ESG ratings and metrics on a monthly basis and as such, the ratings in Morningstar may not necessarily reflect current Sustainalytics’ scores for the company. For the most up to date rating and more information, please visit: sustainalytics.com/esg-ratings/ opens in a new tab.

© Morningstar 2025. All Rights Reserved. The data and analyses herein do not constitute investment advice; is provided solely for informational purposes; is not an offer to buy/sell a security; and is not warranted to be correct, complete, or accurate. Morningstar is not responsible for any trading decisions, damages or losses resulting from, or related to, the data and analyses or their use. Financial Professionals: This report may not meet all applicable presentation and/or disclosure standards to which you are subject to by a regulator and may need to be supplemented with another report or additional data and/or disclosures. Review carefully before sharing this report and contact your Compliance team with any questions. The ESG-related information, methodologies, tool, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.